Pilot Trial: Psilocybin Therapy Achieves 75% Remission in Veterans With Treatment-Resistant PTSD

For thousands of U.S. military veterans, returning home from combat marks the beginning of a different, internal war. Severe post-traumatic stress disorder (PTSD) can be profoundly disabling, characterized by intrusive nightmares, hypervigilance, and an inability to find stillness [2]. While conventional treatments like SSRI antidepressants and standard talk therapy help many, a significant subset of veterans develop treatment-resistant PTSD, leaving them vulnerable to long-term disability and an elevated risk of suicide [6]. The urgent need for alternative interventions has driven researchers to explore unconventional avenues, leading to a renewed scientific focus on psychedelic compounds [3].[2][3][6]

A groundbreaking pilot trial published in the journal Communications Medicine offers a compelling new signal of hope for this hard-to-treat population [1]. Researchers at Ohio State University's Center for Psychedelic Drug Research and Education (CPDRE) conducted the first U.S. clinical trial evaluating psilocybin-assisted therapy specifically in military veterans [2]. The results significantly exceeded typical clinical expectations: one month after completing the protocol, 75% of the participants achieved full remission, meaning their symptoms no longer met the diagnostic criteria for PTSD [1, 5].[1][2][5]

The open-label trial recruited 12 veterans, aged 21 to 64, all of whom suffered from severe PTSD that had persisted despite at least six months of psychotherapy and three months on standard antidepressant medications [3]. At the start of the study, the participants' average clinician-rated symptom score hovered near 40—a level indicative of severe, daily impairment [6]. The trial was primarily designed to test the safety of administering synthetic psilocybin to this specific demographic, a requirement set by the FDA before larger efficacy trials could proceed [3].[3][6]

Crucially, the intervention was not simply a pharmacological treatment, but a highly structured 11-week therapeutic protocol [4]. Researchers emphasize that the non-drug psychotherapy acts as an essential substrate, which the psilocybin then catalyzes to achieve therapeutic breakthroughs [1]. The process began with approximately eight hours of preparatory talk therapy spread across four weekly sessions [3]. This phase was designed to build profound trust between the veterans and their clinicians, establishing a safe psychological container and setting clear intentions for the dosing experience [6].[1][3][4][6]

Following the preparation phase, participants underwent two supervised dosing sessions spaced two to three weeks apart [5]. In a controlled, comfortable clinical setting, the veterans received a 15-milligram dose of synthetic psilocybin during the first session, followed by a higher 25-milligram dose during the second [1]. During these day-long sessions, patients wore eyeshades and listened to curated music, allowing them to direct their attention inward while supported by two trained therapists [3].[1][3][5]

The physiological and psychological effects of psilocybin temporarily alter brain connectivity, particularly by quieting the default mode network—a system often hyperactive in trauma survivors [1]. This neurological shift can allow patients to revisit and process deeply entrenched traumatic memories without triggering the overwhelming fear and panic responses that typically block progress in standard therapy [2]. Following each dosing session, the veterans completed six to eight hours of integration therapy, designed to help them make sense of their psychedelic experiences and apply those insights to their daily lives [4].[1][2][4]

The clinical outcomes measured at the one-month follow-up were striking. Clinician-administered assessment scales revealed an average decrease of 27.5 points in overall PTSD symptom severity [1]. Nine of the twelve veterans met the rigorous thresholds for both treatment response (a 50% reduction in symptoms) and full remission [3]. Furthermore, ten of the participants cleared the 15-point mark, which is considered the threshold for clinically meaningful improvement in daily functioning [3].[1][3]

The human impact of these numbers is profound. Zachariah Collett, a 25-year-old U.S. Army veteran who served a 28-month combat tour in Iraq, participated in the trial after being medically retired [4]. Collett described being "absolutely tortured by the internal struggle" and the constant noise in his head before the treatment [4]. Following the psilocybin-assisted therapy, he credited the protocol with helping him rediscover a sense of peace and stillness that had eluded him for years [2].[2][4]

Safety, the primary endpoint of the pilot study, was clearly established [6]. The protocol produced no serious adverse events, and crucially, researchers observed no increase in suicidal ideation or behavior among the participants [1]. Vital signs, including blood pressure and heart rate, remained within protocol-defined safety limits throughout the dosing sessions [6]. The most common side effect was a mild to moderate headache following the administration of the drug, which resolved without significant medical intervention [3].[1][3][6]

The success of this trial arrives amid a broader paradigm shift within the Department of Veterans Affairs regarding psychedelic medicine [2]. The VA is currently involved in 19 active clinical trials focused on psychedelic therapies for mental health conditions, supported by more than $23 million in external funding [2]. This includes a recently announced trial evaluating MDMA-assisted therapy for severe mental health disorders, signaling a growing institutional willingness to explore once-taboo compounds [2].[2]

Despite the highly encouraging results, researchers are careful to contextualize the findings [6]. As an open-label pilot trial with only 12 participants, the study lacked a placebo control group [3]. This design makes it difficult to entirely rule out expectancy bias—the phenomenon where patients experience improvement simply because they strongly believe the novel treatment will work [5]. The study's authors, including senior researcher Alan Davis, acknowledge that larger, randomized controlled trials are necessary to definitively prove efficacy [4].[3][4][5][6]

There are also ongoing debates within the psychiatric field about the exact ratio of the treatment's success [4]. Researchers are actively trying to determine how much of the remission is driven by the pharmacological effect of the psilocybin, how much by the intensive 14-to-16 hours of psychotherapy, and how much by the unique synergy of the two [4]. However, data from the trial showed that while symptoms began to decline during the preparatory therapy, the most dramatic reductions occurred immediately following the dosing sessions [6].[4][6]

Looking ahead, the research team plans to assess the six-month outcomes for this cohort to determine the durability of the remission [6]. They are also seeking funding for larger Phase 2 and Phase 3 trials, which will be required before the FDA would consider approving psilocybin as a prescription treatment [2]. For now, psilocybin remains a Schedule I controlled substance, but for the veterans who found relief in this pilot study, the therapy has already provided a life-altering reprieve from the shadow of trauma [3].[2][3][6]